In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Valeant Pharmaceuticals International Inc. (NYSE:VRX) reported that Va Partners I, Llc. has picked up 16,937,431 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Va Partners I, Llc. to a total of 16,937,431 representing a 4.9% stake in the company.
For those not familiar with the company, Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
A glance at Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s key stats reveals a current market capitalization of 3.87 Billion based on 341.19 Million shares outstanding and a price at last close of $11.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-15, De picked up 10,000 at a purchase price of $10.80. This brings their total holding to 25,190 as of the date of the filing.
On the sell side, the most recent transaction saw Pershing unload 18,114,432 shares at a sale price of $11.00. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Valeant Pharmaceuticals International Inc. (NYSE:VRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
